. 2020 Jul 22;93(2):775–785. doi: 10.1002/jmv.26302

Table 2.

Study outcomes in the intervention and control groups with odds ratios

Outcome	Intervention group only	Intervention group studies common with control group	Control group only	Odds ratio
All‐cause mortality	11.9% (95% CI: 7.7%‐16.1%) (n = 2071)	16.2% (95% CI: 8.8%‐23.6%) (n = 1557)	15.4% (95% CI: 9.1%‐21.6%) (n = 1110)	1.22 (95% CI: 0.85‐1.75; I ² = 39%) (n = 2667)
Mechanical ventilation rate	18.6% (95% CI: 10.9%‐26.3%) (n = 1456)	13.5% (95% CI: 7%‐19.9%) (n = 1382)	9.8% (95% CI: 4.5%‐ 15.2%) (n = 935)	1.58 (95% CI: 0.60‐4.15; I ² = 85%) (n = 2317)
Antiviral clearance rate	80% (95% CI: 70.7%‐89.4%) (n = 393)	74.9% (95% CI: 59.5%‐90.3%) (n = 257)	66.8% (95% CI: 42.6%‐91.1%) (n = 204)	1.86 (95% CI: 0.76‐4.54; I ² = 58% (n = 461)
Clinical recovery rate	79.7% (95% CI: 78.9%‐ 88.4%) (n = 558)	64.1% (95% CI: 51.5%‐76.8%) (n = 340)	56.9% (95% CI: 43.8%‐69.9%) (n = 243)	1.41 (95% CI: 0.99‐2.02, I ² = 0%) (n = 583)
Progression to severe disease	11.6% (95% CI: 5.4%‐17.8%) (n = 387)	13.4% (95% CI: 2.2%‐24.6%) (n = 218)	12.8 (95% CI: 4.8%‐ 20.8%) (n = 168)	1.19 (95% CI: 0.67‐2.13; I ² = 0%) (n = 386)
Radiological improvement rate	86.3% (95% CI: 77.2%‐95.5%) (n = 140)	83.6% (95% CI: 67.6%‐99.7%) (n = 107)	82.6% (95% CI: 60.3%‐100%) (n = 60)	1.02 (95% CI: 0.13‐8.07; I ² = 63%) (n = 167)
Discharge rate	69.8% (95% CI: 60.3%‐79.3%) (n = 1374)	68.6% (95% CI: 62.2%‐75%) (n = 1171)	78.6% (95% CI: 67.8%‐89.4%) (n = 800)	0.55 (95% CI: 0.29‐1.03; I ² = 81%)
Adverse events rate	23.3% (95% CI: 12.1%‐34.5%) (n = 791)	34% (95% CI: 13.9%‐54.1%) (n = 436)	29.5% (95% CI: 9.4%‐49.6%) (n = 310)	1.44 (95% CI: 0.70‐2.94; I ² = 62%) (n = 754)